Disclaimer: This blog post focuses on a new piece of research from Rethink Priorities. I was not involved with the funding or execution of this research, and therefore write this piece merely as a consumer. However, I am the Executive Director of Giving Green and a board member of Rethink Priorities, and acknowledge that these affiliations may bias my...
I am writing up two charity ideas I’ve wanted to investigate, but haven’t been able to, in the hopes someone will investigate them further. If you end up investigating either, I'd be most interested to see what conclusions you come to!
Vulture preservation as a global health intervention
Since the mid 1990's the vulture population in India has been rapidly declining. The reason is due to a few chemicals which are fed to livestock, which is highly poisonous to vultures.
...
Summary
This post will summarize the trajectory of Wild Animal Initiative’s field-building for wild animal welfare science so far, along with patterns and indicators we want to see more of going forward. Beginning with an initial phase focused on establishing credibility and awareness of the field, through a second phase that has placed more emphasis on the distinctiveness and broad priorities of the field, we are now moving into a third phase designed to co...
New anti-malaria treatment clears phase 3 trials.
I just found that there is a new anti-malarial alternative to artemisinin, the most common antimalarial chemical, which has successfully completed Phase 3 trials. Its nickname is GanLum and apparently has quite powerful effects:
This is an important advance because resistance to artemisinin is one of the growing concerns in the fight against malaria.
You may read more in https://www.npr.org/sections/goats-and-soda/2025/11/12/g-s1-97487/malaria-drug-new and https://www.mmv.org/newsroom/news-resources-search/phase-3-trial-next-generation-malaria-treatment-ganaplacide-lumefantrine .
Very interesting! And very hopeful! Thanks for sharing!